Promising First-Line Immunotherapy Findings in Hodgkin Lymphoma: Complete Response of 100%
The study yielded a complete response rate of 100% across 33 subjects.
The study yielded a complete response rate of 100% across 33 subjects.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Associations attenuated but remained significant after adjustment for steroid use.
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
A retrospective cohort study explored outcomes for pregnant women with HL who received antenatal chemotherapy compared with a match cohort of nonpregnant women.
Study sought to determine if response to upfront treatment in children and adolescents with Hodgkin lymphoma is influenced by race/ethnicity.
A single-center retrospective cohort analysis revealed real-world insights into possible treatments for elderly patients with Hodgkin lymphoma.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.